



## **CaroGen Corporation Awarded \$500,000 in Seed Funding from Connecticut Innovations**

**Hamden, CT – December 10, 2014** – CaroGen Corporation announced today that it has been awarded \$500,000 from the Connecticut Bioscience Innovation Fund (CBIF) to support continued development of CaroGen’s therapeutic Hepatitis B Virus (HBV) vaccine for chronically infected individuals. CaroGen is the first Connecticut company to receive support from the recently created CBIF program. The award will allow CaroGen to complete preclinical study endpoints with its Virus-like Vesicle (VLV) technology and selection of a clinical candidate. It is estimated that over 240 million people suffer from chronic HBV across the global population with approximately 1.4 million in the U.S. alone. Chronic infection leads to cirrhosis and 80% of all liver cancers resulting in over 500,000 deaths per year from this form of cancer.

“We are so pleased to receive the continued support from Connecticut Innovations and to be one of the first companies to receive support from the CBIF. The funds will add great value to CaroGen through the advancement our lead program in HBV,” said Bijan Almassian, Ph.D., Chief Executive Officer of CaroGen. “The work to be supported with this funding will further validate our VLV vaccine platform and demonstrate the capacity to develop vaccines against other devastating diseases.” The majority of the research will be conducted in the laboratories of Dr. John Rose at Yale University as part of a sponsored research agreement between the University and CaroGen.

### **About CaroGen**

CaroGen Corporation is an emerging vaccine company creating potentially transformative vaccines against infectious diseases and immunotherapies for cancer. CaroGen is using its proprietary virus-like vesicle vaccine technology as an innovative approach to drive robust immunity against complex chronic diseases. Additional information about CaroGen is available on the company’s website, [www.carogencorp.com](http://www.carogencorp.com).

### **Media Contact**

Bijan Almassian  
Chairman & CEO  
295 Washington Ave, Suite 4N  
Hamden, CT 06518  
Tel: (203) 230-8596  
email: [balmassian@carogencorp.com](mailto:balmassian@carogencorp.com)